GJGeorge R. Jackson

George R. Jackson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


George R. Jackson has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Tzu-Kang Sang

    Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan

    4 shared publications
  • Anuradha Ratnaparkhi

    Department of Neurology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America

    2 shared publications
  • George M. Lawless

    Department of Neurology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America

    2 shared publications
  • Antony Rodriguez

    Department of Cell Biology University of Texas Southwestern Medical Center 75390 Dallas TX USA

    1 shared publication
  • Carlos A Brown

    Neurogenetics Program, Department of Neurology, University of California-Los Angeles, School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095 USA

    1 shared publication
  • Chenjian Li

    Department of Neurology and Neuroscience Weill Medical College of Cornell University 10021 New York NY USA and

    1 shared publication

Latest Publications

  • Open Access

    A Drosophila Model of ALS: Human ALS-Associated Mutation in VAP33A Suggests a Dominant Negative Mechanism

    by Anuradha Ratnaparkhi, George M. Lawless, Felix E. Schweizer, Peyman Golshani, George R. Jackson

    ALS8 is caused by a dominant mutation in an evolutionarily conserved protein, VAPB (vesicle-associated membrane protein (VAMP)-associated membrane protein B)/ALS8). We have established a fly model of ALS8 using the corresponding mutation in Drosophila VAPB (dVAP33A) and examined the effects of this mutation on VAP function using genetic and morphological analyses. By simultaneously assessing the effects of VAPwt and VAPP58S on synaptic morphology and structure, we demonstrate that the phenotypes produced by neuronal expression of VAPP58S resemble VAP loss of function mutants and are opposite those of VAP overexpression, suggesting that VAPP58S may function as a dominant negative. This is brought about by aggregation of VAPP58S and recruitment of wild type VAP into these aggregates. Importantly, we also demonstrate that the ALS8 mutation in dVAP33A interferes with BMP signaling pathways at the neuromuscular junction, identifying a new mechanism underlying pathogenesis of ALS8. Furthermore, we show that mutant dVAP33A can serve as a powerful tool to identify genetic modifiers of VAPB. This new fly model of ALS, with its robust pathological phenotypes, should for the first time allow the power of unbiased screens in Drosophila to be applied to study of motor neuron diseases.


  • Open Access

    Guide to Understanding Drosophila Models of Neurodegenerative Diseases

    by George R Jackson

    Demystifying how genetic studies inDrosophila inform human disease conditions, this article highlights two studies that identify genetic modifiers of neurodegeneration.


  • Open Access

    ADrosophilaModel of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine

    by Tzu-Kang Sang, Hui-Yun Chang, George M. Lawless, Anuradha Ratnaparkhi, Lisa Mee, Larry C. Ackerson, Nigel T. Maidment, David E. Krantz, George R. Jackson

    Mutations in human parkin have been identified in familial Parkinson's disease and in some sporadic cases. Here, we report that expression of mutant but not wild-type human parkin inDrosophilacauses age-dependent, selective degeneration of dopaminergic (DA) neurons accompanied by a progressive motor impairment. Overexpression or knockdown of theDrosophilavesicular monoamine transporter, which regulates cytosolic DA homeostasis, partially rescues or exacerbates, respectively, the degenerative phenotypes caused by mutant human parkin. These results support a model in which the vulnerability of DA neurons to parkin-induced neurotoxicity results from the interaction of mutant parkin with cytoplasmic dopamine.


  • Drosophila models of neurodegenerative disease

    by Tzu-Kang Sang, George R. Jackson

    Over the last two decades, a number of mutations have been identified that give rise to neurodegenerative disorders, including familial forms of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Although in most cases sporadic cases vastly outnumber familial forms of such diseases, study of such inherited forms has the potential to provide powerful clues regarding the pathophysiological basis of neurodegeneration. One powerful approach to analyzing disease mechanisms is the development of transgenic animal models, most notably in the mouse. However, development and analysis of such models can be costly and time consuming. Development of improved transgenic technologies have contributed to the development of Drosophila models of a number of neurodegenerative disorders that have shown striking similarities to the human diseases. Moreover, genetic screens using such models have begun to unravel aspects of the pathophysiological basis of neurodegenerative disorders. Here, we provide a general overview of fly models pertinent to trinucleotide repeat expansion disorders, Alzheimer’s, and Parkinson’s diseases, and highlight key genetic modifiers that have been identified to date using such models.


  • Open Access

    Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis

    by Tzu-Kang Sang, Chenjian Li, Wencheng Liu, Antony Rodriguez, John M. Abrams, S. Lawrence Zipursky, George R. Jackson

    Huntington's disease (HD) is caused by expansion of a polyglutamine tract near the N-terminal of huntingtin. Mutant huntingtin forms aggregates in striatum and cortex, where extensive cell death occurs. We used a Drosophila polyglutamine peptide model to assess the role of specific cell death regulators in polyglutamine-induced cell death. Here, we report that polyglutamine-induced cell death was dramatically suppressed in flies lacking Dark, the fly homolog of human Apaf-1, a key regulator of apoptosis. Dark appeared to play a role in the accumulation of polyglutamine-containing aggregates. Suppression of cell death, caspase activation and aggregate formation were also observed when mutant huntingtin exon 1 was expressed in homozygous dark mutant animals. Expanded polyglutamine induced a marked increase in expression of Dark, and Dark was observed to colocalize with ubiquitinated protein aggregates. Apaf-1 also was found to colocalize with huntingtin-containing aggregates in a murine model and HD brain, suggesting a common role for Dark/Apaf-1 in polyglutamine pathogenesis in invertebrates, mice and man. These findings suggest that limiting Apaf-1 activity may alleviate both pathological protein aggregation and neuronal cell death in HD.


  • Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila

    by George R Jackson, Martina Wiedau-Pazos, Tzu-Kang Sang, Naveed Wagle, Carlos A Brown, Sasan Massachi, Daniel H Geschwind